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Abstract For certain subgroups within people living with the human immunodefi-
ciency virus (HIV) [active tuberculosis (TB), pregnant women, children <5 years
old, and serodiscordant couples], the World Health Organization recommends
antiretroviral therapy (ART) irrespective of CD4 count. Another subgroup which
has received increased attention is ‘‘HIV-infected presumptive TB patients without
TB”. In this study, we assess the proportion of HIV-infected presumptive TB patients
eligible for ART in Karnataka State (population 60 million), India. This was a cross-
sectional analysis of data of HIV-infected presumptive TB patients diagnosed in
May 2015 abstracted from national TB and HIV program records. Of 42,585 presump-
tive TB patients, 28,964 (68%) were tested for HIV and 2262 (8%) were HIV positive.
Of the latter, 377 (17%) had active TB. Of 1885 ‘‘presumptive TB patients without
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active TB”, 1100 (58%) were already receiving ART. Of the remaining 785 who were
not receiving ART, 617 (79%) were assessed for ART eligibility and of those, 548 (89%)
were eligible for ART. About 90% of ‘‘HIV-infected presumptive TB patients without
TB” were eligible for ART. This evidence supports a public health approach of start-
ing all ‘‘HIV-infected presumptive TB patients without TB” on ART irrespective of
CD4 count in line with global thinking about ‘test and treat’.
 2016 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
1. Introduction
With an estimated 36.9 million people living with
HIV (PLHIV), 2.0 million new HIV infections, and
1.2 million deaths in 2014, HIV continues to be
the most common infectious cause of mortality in
the world and has claimed >34 million lives so far
[1]. Antiretroviral therapy (ART) is life-saving for
PLHIV, and by the end of March 2015, about 15
million PLHIV were receiving ART. HIV is the only
infectious disease where treatment is initiated only
after it becomes clinically severe (assessed using
CD4 counts). There have been various reasons for
this strategy which include prioritizing toxic drugs
for those with highest risk of progressing to AIDS,
concerns about nonadherence, and risk of drug
resistance if treatment is started too early.
However, this situation is fast changing with the
availability of newer and safer antiretroviral
medicines and the evidence that early ART is ben-
eficial even in asymptomatic PLHIV [2,3].
The World Health Organization (WHO) and the
Joint United Nations Programme on HIV/AIDS
(UNAIDS) have both embarked on an ambitious
vision of ‘‘90-90-90”: to detect 90% of all HIV-
infected patients in the community, treat 90% of
those detected with ART, and achieve viral sup-
pression in 90% of those treated [4]. Given this,
there is an increased demand from civil society
organizations and patient groups to move toward
a ‘‘test and treat” strategy. In 2013, WHO raised
the threshold for ART initiation to a CD4 count
6500 cells/lL in adults, adolescents, and children
aged 5 years and above. For certain patient groups
like PLHIV having active tuberculosis (TB) disease,
hepatitis B virus infection with severe chronic liver
disease, pregnant and breast feeding women, chil-
dren aged under 5 years, and those living in a
serodiscordant relationship, ART is recommended
irrespective of CD4 count (akin to a ‘‘test and
treat” strategy) (Table 1) [5]. Another such
subgroup which has caught global attention is
‘‘presumptive TB patients” (previously called TB
suspects and defined as people with cough for
2 weeks or more with or without other symptoms
suggestive of TB), but without TB.
Several studies from sub-Saharan African coun-
tries and Asia show a high HIV prevalence among
patients with presumptive TB ranging from 10% to
64%, sometimes even higher than the HIV
prevalence among TB patients, prompting WHO to
recommend routine HIV testing in such patients
[6–14]. A prospective study from Zimbabwe
showed that HIV-infected presumptive TB patients
are a neglected group with only 15% getting ART,
while about 85% had CD4 cell counts < 350 cells/lL
and were eligible for ART at the time [4]. However,
no study has systematically assessed this aspect in
India.
Hence, in this study, we aim to determine the
number of HIV-infected presumptive TB patients
eligible for ART in a large south Indian state of Kar-
nataka. The specific objectives were to determine
among a cohort of presumptive TB patients (strat-
ified by whether they have TB or not) attending the
microscopy centers of Karnataka in May 2015: (1)
number (proportion) ascertained for HIV status
and found HIV positive; and (2) among HIV-
infected patients, (a) number assessed for ART
eligibility and found ART eligible and (b) number
(proportion) initiated on ART.
2. Materials and methods
2.1. Study design
This was a cross-sectional study involving sec-
ondary analysis of data routinely recorded under
the Revised National TB Control Programme
(RNTCP) and National AIDS Control Programme
(NACP).
2.2. Setting
India is considered a country with a concentrated
HIV epidemic and contributes to about 10% of the
global burden in absolute terms [1]. The HIV epi-
demic in India is showing a declining trend and in
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2011, about 2.1 million people were living with HIV
in India with an estimated 0.12 million new
infections and 0.15 million deaths [15].
Karnataka State has an estimated 0.21 million
PLHIV in 2011 and accounts for about 10% of the
country’s HIV burden [15]. Hence, the state has
been classified as ‘‘high priority” for HIV interven-
tions by the National AIDS Control Organization
(NACO) in India on the basis of consistently high
HIV seroprevalence rates of >1% during sentinel
surveillance at antenatal clinics [16,17]. In the
state, TB control program services are available
through a decentralized network of peripheral
health institutions which provide general health
services including diagnosis and treatment for TB.
Patients with presumptive TB are identified at
the peripheral health institutions and referred for
sputum smear microscopy to designated micro-
scopy centers (DMCs), which are geographically dis-
tributed, each covering a population of 0.05–0.1
million. In situations where the patient is unable
to physically visit the DMC, the sputum is collected
and transported using existing systems and health-
care workers in the general health system or non-
governmental organizations. The diagnosis of TB
is made in accordance with national guidelines.
Presumptive TB patients are first tested using spu-
tum smear microscopy and if found to be positive
for acid-fast bacilli, patients are diagnosed as
‘‘smear-positive pulmonary TB” and initiated on
treatment. Patients with negative smears are given
antibiotics for 7–10 days and are tested for smear
microscopy again if symptoms persist. If smears
are negative in repeat sputum microscopy, patients
Table 1 Comparison of World Health Organization (WHO) guidelines for antiretroviral therapy (ART) initiation among
people living with human immunodeficiency virus (HIV) in the year 2010 and 2013.
Population Target population 2010 ART guidelines 2013 ART guidelines
Adults and
adolescents
HIV-infected individuals CD4 count 6350 cells/mm3 or
WHO clinical Stage 3 or 4
regardless of CD4 cell count
CD4 count 6500 cells/
mm3 or WHO clinical
Stage 3 or 4 regardless of
CD4 cell count
HIV-infected pregnant
and breastfeeding
women
CD4 count 6350 cells/mm3
regardless of clinical symptoms
or WHO clinical Stage 3 or 4
regardless of CD4 cell count
Regardless of CD4 cell
count or WHO clinical
stage
HIV-infected partners in
serodiscordant couple
relationship(s)
No recommendation established
HIV/TB coinfection Presence of active TB disease,
regardless of CD4 cell count
No change
HIV/HBV coinfection Evidence of chronic active HBV
disease, regardless of CD4 cell
count
Evidence of chronic HBV
disease with advanced
stage liver disease (e.g.,
cirrhosis), regardless of
CD4 cell count
Children HIV-infected children
P5 years old
CD4 6350 cells/mm3 or WHO
clinical Stage 3 or 4 regardless
of CD4 cell count
CD4 count 6500 cells/
mm3 or WHO clinical
Stage 3 or 4 regardless of
CD4 cell count
HIV-infected children 1–
5 years old
1. Between 12 and 24 months of
age, regardless of CD4 count or
WHO clinical stage
Regardless of CD4 cell
count and clinical stage
2. Between 24 and 59 months of
age with CD4 count of
6750 cells/mm3 or CD4% 625,
or whichever is lower,
regardless of WHO clinical stage
HIV-infected infants
<1 year old
All infants, regardless of CD4
cell count and clinical stage
No change
ART = antiretroviral therapy; HBV = hepatitis B virus; HIV = human immunodeficiency virus; TB = tuberculosis; WHO = World Health
Organization.
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undergo chest radiography. A diagnosis of smear-
negative pulmonary TB is made if lesions consistent
with TB are found on a chest radiograph. Patients
with a normal chest X-ray and/or whose symptoms
subsided by the trial of antibiotics were catego-
rized as ‘‘presumptive TB without TB”. All diag-
nosed TB patients are treated with standardized
fully intermittent thrice weekly short course regi-
mens (6–9 months) administered under direct
observation. Such patients are registered at one
of the 177 subdistrict level TB program manage-
ment units according to Indian program guidelines
[18].
As per national policy, HIV status is routinely
ascertained for all presumptive TB patients, and
HIV-infected TB patients are referred to ART cen-
ters for initiation on ART and cotrimoxazole pre-
ventive therapy [19]. HIV status is ascertained at
‘‘integrated counseling and HIV testing centers”
spread throughout the state, which are usually col-
located with sputum microscopy services. HIV is
diagnosed based on three positive rapid tests as
per national guidelines [20]. Free ART is provided
through a network of 64 ART centers (with at least
1 ART center in every district), where HIV-infected
patients (including TB patients) are offered treat-
ment and care. There are 194 link-ART centers in
the state which offer follow up services at decen-
tralized locations for HIV patients who are clini-
cally stable on ART. These service delivery sites
under NACP follow the national guidelines for
counseling, testing, care, and treatment of HIV-
infected patients [21]. In line with the higher bur-
den of HIV, there is a higher density of HIV testing
and care centers in the northern parts of the state
[22].
2.3. Study population and study period
All patients with presumptive TB examined for
diagnostic smear microscopy at the DMCs of Kar-
nataka State in May 2015 constituted the study
population. Patients attending for ‘‘re-
examination” and follow-up examination were not
included.
2.4. Data collection procedure and data
variables
For objective 1, we collected aggregate data on
the number of presumptive TB patients examined
for smear microscopy, the number tested for HIV,
and the number who were HIV positive. For the
HIV-infected presumptive TB patients, individual
patient data were collected using a structured,
pretested data collection pro forma. The data
variables included laboratory number, age, sex,
TB diagnosis (smear-positive TB/smear-negative
TB/extrapulmonary/no TB), TB treatment (yes/
no), WHO clinical staging, latest CD4 lymphocyte
count (at the time of registration for newly
detected HIV patients or latest available count
for patients already receiving ART), and ART status
(already on ART before visiting DMC/started on ART
after DMC visit/not started on ART). These
variables were extracted from the TB laboratory
register and TB treatment register of RNTCP and
pre-ART patient register, patient ART card, and
HIV-TB register of NACP. Information on whether
the patient is diagnosed as smear-negative TB or
extrapulmonary TB was extracted by referring to
the TB register.
Data were collected by the ‘‘district PMDT/
TBHIV coordinators” working for RNTCP and trained
in the study protocol under the supervision of WHO
consultants and state-level government program
officers working for the TB and HIV programs.
2.5. Data entry and analysis
Aggregate information from each district was col-
lected using an Excel format. For capture of
patient-wise data, we used a combination of three
open access sources (EpiData for data entry, Drop-
box for sharing data and TeamViewer for trouble-
shooting remotely). The technique has been
detailed elsewhere [23]. Data entry was done by
the data entry operators of the respective districts,
trained for the purpose. Double data entry, valida-
tion, and analysis were done using EpiData soft-
ware (version 3.1 for entry and version 2.2.2.182
for analysis, EpiData Association, Odense, Denmark).
ART eligibility was assessed using WHO-2013
ART guidelines (CD4 count of <500, WHO clinical
staging 3 and 4, children <5 years old, all HIV-TB
patients), as the NACP in India has agreed in
principle to adopt the recommendations [24,25].
In addition, if a patient was documented as
‘‘ART eligible” in the records and started on ART
(even though there was no full documentation of
CD4 counts and/or WHO clinical staging), we
considered such patients to be eligible for ART
for this analysis.
2.6. Ethics
Administrative approval to conduct the study and
access the data was obtained from the State
Tuberculosis Cell of Government of Karnataka.
Ethics approval was obtained by the Ethics Advisory
Group of International Union against Tuberculosis
and Lung Disease, Paris, France. Since the study
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involved a secondary analysis of routine program
records, the need for individual patient consent
was waived by the ethics committee.
3. Results
A total of 42,585 presumptive TB patients under-
went sputum smear microscopy in 680 DMCs of 31
districts of Karnataka State, of whom 28,964
(68%) were ascertained for HIV status and 2262
(8%) were found to be HIV positive (Fig. 1). The
median (interquartile range, IQR) age of HIV-
infected patients was 38 (30–45) years and about
half of them were males.
3.1. TB patients: diagnosis, TB treatment,
and ART
Of 2262 HIV-infected presumptive TB patients, 377
(17%) were diagnosed to have active TB and of
them, 370 (98%) were initiated on TB treatment.
Of 377 TB patients, 194 (52%) had smear-positive
pulmonary TB, 122 (32%) had smear-negative pul-
monary TB, and 61 (16%) had extra pulmonary TB.
Of the TB patients, 210 (57%) were receiving ART
prior to TB diagnosis. Of the remaining 167, 122
(73%) were started on ART after TB diagnosis. Thus,
a total of 332 (88%) were receiving ART during TB
treatment.
Initiated on ART 
405 (74%) 
Assessed for ART eligibility
617 (79%) 
ART Eligible
548 (89%) 
On prior ART
1100 (58%) 
Not on prior ART 
785 (42%) 
Number with TB
377 (17%) 
Number without TB
1885 (83%) 
Total number of presumptive 
TB patients
42585 
Number ascertained for HIV 
status
28964 (68%) 
Number HIV-positive
2262 (8%) 
Fig. 1 ART eligibility among human immunodeficiency virus (HIV)-infected presumptive tuberculosis (TB) patients in
Karnataka, India, 2015. ART = antiretroviral therapy; HIV = human immunodeficiency virus; TB = tuberculosis. On prior
ART-Person who was receiving ART prior to the current visit to sputum microscopy center (TB Clinic).
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3.2. Presumptive TB patients without active
TB: ART eligibility and ART initiation
Among the 1885 ‘‘presumptive TB patients without
active TB”, 1100 (58%) were already receiving ART
prior to the current visit. Among the remaining 785
who were not receiving ART, 617 (79%) were
assessed for ART eligibility and among them, 548
(89%) were found to be ART eligible as per WHO
2013 ART guidelines. Patients who were assessed
for ART eligibility were similar to those not
assessed by age (median age 39 years and 40 years,
respectively, p = 0.95) and sex (proportion male
49% and 51%, respectively, p = 0.54). The CD4 dis-
tribution and WHO clinical staging information of
548 patients who were found to be eligible for
ART is shown in Table 2. Of those found to be ART
eligible, 405 (74%) were initiated on ART (Fig. 1).
3.3. Median CD4 counts
Of 2262 patients, 1998 (88%) had information on
CD4 counts. The median (IQR) CD4 count among
patients with active TB was 194 (100–333) as com-
pared to 264 (123–438) among ‘‘presumptive TB
patients without active TB” (p < 0.001). Among
those without active TB, median (IQR) CD4 count
was significantly higher (p < 0.001) among those
receiving ART at 281 (147–450) cells/lL as com-
pared to those not on ART at 226 (92–399) cells/lL.
4. Discussion
These findings confirm our hypothesis and showed
that nine out of 10 HIV-infected presumptive TB
patients (without TB) are eligible for ART as per
current WHO guidelines. This, too, is an underesti-
mate, as we did not assess all the criteria of ART
eligibility in our study. For example, we did not
have any information about whether the patients
in our study had coexisting hepatitis-B infection
with severe liver disease, or if they were pregnant
or living in a serodiscordant relationship. Some
studies have indicated that nearly 75% of PLHIV in
India are serodiscordant [26,27]. If we apply this
figure to our cohort, then nearly all HIV-infected
presumptive TB patients would be eligible for
ART. Hence, as a public health approach to ART ini-
tiation, there is a strong case to be made for rec-
ommending that all HIV-infected presumptive TB
patients should be initiated on ART irrespective
of CD4 count.
There are a number of advantages with adoption
of this recommendation. First, this is likely to
improve uptake of ART (possibly by removing barri-
ers associated with CD4 testing) in this vulnerable
group. We have observed this in the past with
HIV-infected TB patients when after adopting a
‘‘test and treat” strategy for TB patients, there
was a significant increase in uptake of ART. The
proportion of HIV-infected TB patients receiving
ART in India increased from 41% in 2008 to 91% in
2014 [22]. This is observed in our study sample
too – nearly 90% of HIV-infected TB patients
received ART as compared to only 74% among those
without TB. Despite high uptake of ART among HIV-
TB patients in India, mortality remains high at 13%,
emphasizing the need for early diagnosis and ART
initiation [22].
Second, this is likely to lead to early diagnosis
and treatment of HIV, thus preventing avoidable
mortality, morbidity, and improving the quality of
Table 2 CD4 counts and World Health Organization (WHO) clinical staging of ‘‘human immunodeficiency virus (HIV)-
infected presumptive tuberculosis (TB) patients without TB” eligible for antiretroviral therapy (ART) in May 2015,
Karnataka State, India.
WHO clinical staging
Baseline CD4
count (cells/lL)
Stage 1 n (%) Stage 2 n (%) Stage 3 n (%) Stage 4 n (%) Unknown n (%) Total n (%)
<50 15 (7) 19 (10) 17 (22) 9 (60) 24 (50) 84 (15)
50–200 68 (32) 86 (44) 34 (45) 5 (33) 8 (17) 201 (37)
201–350 67 (31) 52 (27) 13 (17) 1 (7) 7 (15) 140 (26)
351–500 47 (22) 24 (12) 7 (9) 0 (0) 8 (17) 86 (16)
P501 14 (7)a 13 (7)a 3 (4) 0 (0) 0 (0) 30 (5)
Unknown 3 (1)a 1 (1)a 2 (3) 0 (0) 1 (2)a 7 (1)
Total 214 195 76 15 48 548
ART = antiretroviral therapy; HIV = human immunodeficiency virus; WHO = World Health Organization.
a These patients (n = 32) were documented as ‘‘antiretroviral therapy (ART) eligible” in the program records and started on ART
even though the CD4/World Health Organization (WHO) staging criteria were either not documented or did not match eligibility
criteria. They were considered ‘‘ART eligible” for the purpose of this analysis.
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life in the long term. HIV testing among presump-
tive TB patients implies moving the HIV testing
intervention to an upstream level in the TB diag-
nostic pathway and hence, patients are diagnosed
earlier on in the natural course of disease. This is
substantiated by higher median CD4 counts in our
study, among presumptive TB patients (without
TB) as compared to those with active TB. If active
TB can be confidently ruled out using more sensi-
tive diagnostic tools such as Xpert MTB/RIF or
mycobacterial culture, such patients could be
potentially eligible for isoniazid preventive ther-
apy, which is known to act synergistically with
ART in preventing TB. A recent randomized con-
trolled trial has shown that early ART, along with
IPT, is likely to provide maximum benefit to PLHIV
in terms of preventing mortality and morbidity
including TB [2].
It is essential to rule out active TB confidently
before starting ART, as not doing so might pose a
higher risk of developing immune reconstitution
inflammatory syndrome.
Third, starting these patients earlier on ART is
likely to improve their immune status. As observed
in our study, the median CD4 counts were higher
among ‘‘HIV-infected presumptive TB patients
without active TB” already receiving ART prior to
the current visit as compared to those who were
not on ART. A previous study from Zimbabwe
showed that not starting these patients on ART
led to high mortality and morbidity [4]. In addition
to individual benefits, early ART is also likely to
have public health benefits – ART reduces the risk
of transmission of HIV to partners [28] and avoids
the operational problem of poor retention in pre-
ART care [29,30].
Fourth, as only about 10% of presumptive TB
patients were not eligible as per current guidelines,
adopting this strategy is not likely to place a large
additional burden on the national ART program in
India. From a public health perspective, this is a
step toward ‘‘immediate and universal ART” for
every person with HIV in line with the vision of NACP
phase IV for the period 2012–2017 [24].
Our study had several strengths. This is the first
study from India examining the issue of ART eligi-
bility among HIV-infected presumptive TB patients.
Since the data come from a large and comprehen-
sive sample of patients in a large state in India, the
results are likely to reflect ground realities and are
generalizable to similar high HIV settings in India.
However, we need more evidence, especially from
low-HIV settings in India, before a national policy
decision can be considered. We used an innovative
method of quality-assured data capture and this
model is likely to be useful in coordinating data
collection in multicenter research studies in
resource-constrained settings.
There were a few limitations mainly related to
our reliance on data collected routinely by the
national TB and HIV programs. However, we
think this is not a major limitation as both TB and
HIV programs in the state of Karnataka are well
supervised and monitored, and hence the quality
of data is likely to be high. Information on ART eli-
gibility (CD4 counts and/or WHO clinical staging)
was missing in about one-fifth of the patients.
Since those assessed for ART eligibility were similar
to those not assessed by age and sex, we think the
results can be extrapolated to those not assessed
for ART eligibility. We did not have any information
on presumptive extrapulmonary TB patients in our
study and this should be a topic of future research.
Although our recommendations are justified as a
public health approach, it is important to study
the long-term outcomes among the subgroup of
patients with CD4 count of >500/mm3 and assess
if they actually benefit by early initiation of ART.
We, however, think early ART will be beneficial
based on the evidence of two randomized con-
trolled trials which have confirmed the benefit of
early ART in preventing death and/or AIDS related
events [2,3]. These trials have also confirmed that
there was no or minimal increase in adverse events
due to early ART initiation, thus allaying any fears
that early ART initiation could be detrimental.
Finally, as the adage goes, ‘‘what gets moni-
tored gets done”. Hence, we need to think about
ways of monitoring the ART uptake among HIV-
infected presumptive TB patients. We propose
the addition of an extra column in the existing TB
laboratory register to capture ART initiation status.
From this, two indicators can be calculated: (1)
proportion of presumptive TB patients ascertained
for HIV; and (2) proportion of HIV-infected pre-
sumptive TB patients receiving ART. These indica-
tors could then be compiled and reported in the
quarterly reports of the TB program from the
peripheral level, to district, to state, and to
national levels, and finally finding a place in global
TB and HIV reports. Future operational research
should test this and/or other models of recording
and reporting to find out the most optimal way
forward.
5. Conclusion
In conclusion, about 90% of ‘‘HIV-infected pre-
sumptive TB patients without active TB” were
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eligible for ART as per WHO-2013 guidelines. As a
public health approach, ‘‘HIV-infected presump-
tive TB patients without TB” is a vulnerable
subgroup qualifying for ‘‘test and treat” strategy
akin to HIV-infected TB patients.
Conflicts of interest
No conflicts of interest have been declared.
Acknowledgments
The authors are thankful to the staff of the State TB Cell
and Karnataka State AIDS prevention society, District TB
Officers and their staff, and the staff of the ART centers
of the state of Karnataka for enthusiastically assisting in
the process of data collection. We would especially like
to thank by name the ‘‘district PMDT/TBHIV co-
ordinators” (Deshpande JR, Surendranath M Malkapur,
Manjesh Kumar R, Prabhakar Gowda, Shauraj S, Patil
PR, Gududaiah, Shivkumar Swamy, Jayteerth S Ashtapu-
tre, Shekara P, Manjunatha BK, Shivanna S, Yathisha
GS, Kishore PV, Srinivasa AD, Ambiger SL, Kencharad-
diyavara DM, Suresh Doddamani, Manjaraj HT, Umapathi
BS, Shashikala HS, Mahesh N, Danana Gouda Patil, Made-
gowda KD, Mahadev KS, Praveen Kumar Hiremath,
Shivananjaiah N, Kumar S, Krishna Kumar R, Pramod
Kumar Thingalaya, Rajendra MS, and Mallareddy) who
were primarily responsible for data collection and the
district data entry operators who painstakingly per-
formed double entry and validation and ensured highest
quality of data. Finally, the authors are grateful to the
HIV-infected presumptive TB patients of Karnataka State
who have indirectly contributed to this learning.
References
[1] UNAIDS. How AIDS changed everything. MDG6: 15 Years, 15
lessons of hope from the AIDS response: Joint United
Nations Programme on HIV/AIDS, Geneva, Switzerland;
2015. Available at: <http://www.unaids.org/sites/de-
fault/files/media_asset/MDG6Report_en.pdf>. Cited 09/
19/2015.
[2] Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou
J, et al. A trial of early antiretrovirals and isoniazid
preventive therapy in Africa. N Engl J Med
2015;373:808–22.
[3] Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S,
Grund B, et al. Initiation of antiretroviral therapy in early
asymptomatic HIV infection. N Engl J Med
2015;373:795–807.
[4] Joint United Nations Programme on HIV/AIDS. An ambitious
treatment target to help end the AIDS epidemic Geneva,
Switzerland 2014. Available at: <http://www.unaids.
org/sites/default/files/media_asset/90-90-90_en_0.pdf>.
Updated 09/19/2015.
[5] World Health Organization. Consolidated guidelines for the
use of antiretroviral drugs for treating and preventing
HIV infection. Recommendations for a public health
approach. June 2013: World Health Organization, Geneva,
Switzerland; 2013. Available at: <http://www.who.int/
hiv/pub/guidelines/arv2013/download/en/index.html>.
Updated 07/03/2013.
[6] Srikantiah P, Lin R, Walusimbi M, Okwera A, Luzze H,
Whalen CC, et al. Elevated HIV seroprevalence and risk
behavior among Ugandan TB suspects: implications for HIV
testing and prevention. Int J Tuberc Lung Dis 2007;11:168–74.
[7] Deribew A, Negussu N, Kassahun W, Apers L, Colebunders R.
Uptake of provider-initiated counselling and testing among
tuberculosis suspects. Ethiop Int J Tuberc Lung Dis
2010;14:1442–6.
[8] Porskrog A, Bjerregaard-Andersen M, Oliveira I, Joaquı´m
LC, Camara C, Andersen PL, et al. Enhanced tuberculosis
identification through 1-month follow-up of smear-negative
tuberculosis suspects. Int J Tuberc Lung Dis 2011;15:459–64.
[9] Odhiambo J, Kizito W, Njoroge A, Wambua N, Nganga L,
Mburu M, et al. Provider-initiated HIV testing and coun-
selling for TB patients and suspects in Nairobi, Kenya. Int J
Tuberc Lung Dis 2008;12(Suppl. 1):S63–8.
[10] Munthali L, Mwaungulu JN, Munthali K, Bowie C, Crampin
AC. Using tuberculosis suspects to identify patients eligible
for antiretroviral treatment. Int J Tuberc Lung Dis
2006;10:199–202.
[11] Dimairo M, Macpherson P, Bandason T, Zezai A, Munyati SS,
Butterworth AE, et al. The risk and timing of tuberculosis
diagnosed in smear-negative TB suspects: a 12 month
cohort study in Harare, Zimbabwe. PLoS One 2010;5:
e11849.
[12] Adjei AA, Adiku TK, Ayeh-Kumi PF, Hesse IFA. Prevalence of
human immunodeficiency virus infection among tuberculo-
sis suspect patients in Accra, Ghana. West Afr J Med
2006;25:38–41.
[13] Naik B, Kumar AMV, Lal K, Doddamani S, Krishnappa M,
Inamdar V, et al. HIV prevalence among persons suspected
of tuberculosis: policy implications for India. J Acquir
Immune Defic Syndr 2012;59:e72–6.
[14] Achanta S, Kumar AMV, Burugina Nagaraja S, Jaju J, Motta
Shamrao SR, Uappaluri R, et al. Feasibility and effective-
ness of provider initiated HIV testing and counseling of TB
suspects in Vizianagaram district, South India. PLoS One
2012;7:e41378.
[15] National AIDS Control Organization, National Institute of
Medical Statistics. Technical Report India HIV Estimates-
2012: Directorate General of Health Services, Ministry of
Health and Family Welfare, Government of India; 2013.
Available at: <http://www.naco.gov.in/upload/Surveillance/
Reports%20&%20Publication/Technical%20Report%20-
%20India%20HIV%20Estimates%202012.pdf>. Cited 09/23/
2015.
[16] Office of the Registrar General and Census Commissioner.
Provisional Population Totals paper-1: 2011 – Karnataka
New Delhi: Government of India; 2011. Available at:
<http://censusindia.gov.in/2011-prov-results/prov_data_
products_karnatka.html>. Cited 05/09/2011.
[17] National AIDS Control Organization. HIV Sentinel Surveil-
lance and HIV Estimation, 2007, A technical brief: Ministry
of Health and Family Welfare, Government of India; 2008.
Available at: <http://naco.gov.in/upload/Surveillance/
Reports%20&%20Publication/HIV%20Sentinel%20Surveil-
lance%20and%20HIV%20Estimation%202007_A%20Technical
%20Brief.pdf>. Cited 09/23/2015.
[18] Central TB Division. Managing the RNTCP in your area – A
Training course (module 1–4): Directorate General of
Health Services, Ministry of Health and Family Welfare,
Government of India; 2005. Available at: <http://tbcin-
dia.gov.in/index1.php?lang=1&level=3&sublinkid=4262&
lid=2906>. Updated 08/12/2012; cited 09/17/2015.
18 A.M.V. Kumar et al.
[19] National AIDS Control Organization, Central TB Division.
National framework for Joint HIV/TB collaborative activi-
ties: Ministry of Health and Family Welfare, Government of
India; 2009. Available at: <http://tbcindia.gov.in/showfile.
php?lid=2857>. Cited 09/23/2015.
[20] National AIDS Control Organization. Guidelines for HIV
Testing: Ministry of Health and Family Welfare, Govern-
ment of India; 2007. Available at: <http://www.naco.gov.
in/NACO/Quick_Links/Publication/Blood_Safety__Lab_
Services/Operational__Technical_guidelines_and_policies/
Guidelines_for_HIV_test/>. Cited 09/23/2015.
[21] National AIDS Control Organization. Operational Guidelines
for Integrated Counselling and Testing Centres: Ministry of
Health and Family Welfare, Government of India; 2008.
Available at: <http://www.naco.gov.in/NACO/Quick_
Links/Publication/Basic_Services/Operational__Technical_
guidelines_and_policies/Operational_Guidelines_for_Inte-
grated_Counseling_and_Testing_Centres/>. Cited 09/23/
2015.
[22] Central TB Division. TB India 2015. Revised National TB
Control Programme Annual Status Report: Directorate
General of Health Services, Ministry of Health and Family
Welfare, Government of India; 2015. Available at: <http://
tbcindia.gov.in/showfile.php?lid=3166. Updated 09/17/
2015>; Cited 09/17/2015.
[23] Kumar AMV, Naik B, Guddemane DK, Bhat P, Wilson N,
Sreenivas AN, et al. Efficient, quality-assured data capture
in operational research through innovative use of open-
access technology. Public Health Action 2013;3:60–2.
[24] National AIDS Control Organization. Shri Ghulam Nabi Azad
launches National AIDS Control Programme-Phase IV: Direc-
torate General of Health Services, Ministry of Health and
Family Welfare, Government of India; 2014. Available
from: <http://pib.nic.in/newsite/PrintRelease.aspx?relid=
103593>. Cited 09/23/2015.
[25] Dodderi SK, Kumar AM, Naik BR, Kanchar A, Rewari BB,
Harries AD. How many people living with HIV will be
additionally eligible for antiretroviral treatment in Kar-
nataka State, India as per the World Health Organization
2013 guidelines?. PLoS One 2014;9:e107136.
[26] Saggurti N, Schensul SL, Verma RK. Migration, mobility and
sexual risk behavior in Mumbai, India: mobile men with
non-residential wife show increased risk. AIDS Behav
2009;13:921–7.
[27] Arora P, Nagelkerke N, Sgaier SK, Kumar R, Dhingra N, Jha
P. HIV, HSV-2 and syphilis among married couples in India:
patterns of discordance and concordance. Sex Transm
Infect 2011;87:516–20.
[28] Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S,
Eron J, Chen YQ, et al. Effects of early versus delayed
initiation of antiretroviral treatment on clinical outcomes
of HIV-1 infection: results from the phase 3 HPTN 052
randomised controlled trial. Lancet Infect Dis
2014;14:281–90.
[29] Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg
DR, Neilands TB, et al. Failure to initiate antiretroviral
therapy, loss to follow-up and mortality among HIV-
infected patients during the pre-ART period in Uganda. J
Acquir Immune Defic Syndr 2013;63:e64–71.
[30] Ganga Devi NP, Ajay KM, Palanivel C, Sahu S, Selvaraj M,
Valan A, et al. Implementation and operational research:
high loss to follow-up among children on pre-ART care
under national AIDS Program in Madurai, South India. J
Acquir Immune Defic Syndr 2015;69:e109–14.
ScienceDirect
Available online at www.sciencedirect.com
ART eligibility among HIV-infected presumptive TB patients in India 19
